1. Home
  2. AEI vs CDXS Comparison

AEI vs CDXS Comparison

Compare AEI & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

HOLD

Current Price

$1.81

Market Cap

119.4M

Sector

Real Estate

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.58

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
AEI
CDXS
Founded
2014
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Major Chemicals
Sector
Real Estate
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
119.4M
141.8M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
AEI
CDXS
Price
$1.81
$1.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
15.6K
3.5M
Earning Date
05-14-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
93.40
43.82
EPS
N/A
N/A
Revenue
$16,238,200.00
$138,590,000.00
Revenue This Year
N/A
$6.35
Revenue Next Year
N/A
$16.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.30
52 Week Low
$0.70
$0.96
52 Week High
$4.55
$3.87

Technical Indicators

Market Signals
Indicator
AEI
CDXS
Relative Strength Index (RSI) 44.98 56.10
Support Level $1.13 $1.57
Resistance Level $2.11 $1.86
Average True Range (ATR) 0.18 0.19
MACD 0.04 0.03
Stochastic Oscillator 48.99 41.55

Price Performance

Historical Comparison
AEI
CDXS

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: